Challenge
M&A and licensing activities in life sciences often face hidden quality risks that can derail timelines, complicate negotiations, or create post-close compliance issues. These challenges intensify in large-scale acquisitions, start-up integrations, and multiple formulation & brand divestments — where speed, regulatory alignment, and operational continuity are all critical.
Our Experience & Approach
With quality leadership experience in more than 30 transactions, including several major corporate acquisitions (local to global leadership involvement), start-up acquisitions at global level, and global start-up integration, we bring structured quality oversight to every stage of the transaction.
- Start-up Integration Success:
For a global start-up integration, we co-developed an operating model that preserved the start-up’s agility while introducing compliance guardrails in a phased approach. This ensured the team could continue running the business without disruption while aligning with corporate GMP standards. - Accelerating Licensing Negotiations:
Created customizable Quality Agreement templates that could be rapidly tailored to specific licensing scenarios, shortening negotiation time and enabling faster market entry. - Streamlining Divestments:
Provided quality leadership in over a dozen divestments, preparing robust, inspection-ready data rooms that enabled smooth expert sessions and built buyer confidence.
Impact
All transactions under our quality leadership closed on schedule, with no critical post-close compliance issues, uninterrupted supply continuity, and retained key operational talent. Our tailored approach ensures that integration or separation supports — rather than disrupts — the underlying business.